TABLE 3.
Regression models for demographic factors and BMI as predictors of interest and barriers to incretin‐based pharmacotherapy for obesity.
| Medication interest a | Concern about side effects b | Concern about needle injection b | Concern about long‐term risks b | Concern about weight regain b | Expectations of weight loss b | |
|---|---|---|---|---|---|---|
| BMI | 0.01 | 0.005 | −0.01 | 0.004 | −0.03 | 0.04 |
| Gender | 0.01 | −0.13 | −0.91** | −0.07 | −0.15 | 0.03 |
| Race | −0.15 | 0.35 | 0.85* | 0.20 | 0.41 | −0.41 |
| Education | 0.74*** | −0.65* | −0.07 | −0.50 | −0.61 | 0.23 |
| Financial stress | 0.07 | −0.14 | −0.28 | −0.12 | 0.07 | −0.21 |
| Comorbidities | −0.67** | −0.61 | −0.91* | −0.33 | 0.58 | 0.06 |
Abbreviation: BMI, Body Mass Index.
a
Linear regression.
a
Linear regression.
b
Ordinal logistic regression.
*p < 0.05, **p < 0.01, ***p < 0.001.